Saturday, February 01, 2020 11:45:16 AM
If we get A Priority Review designation means FDA’s goal is to take action on an application within 6 months.
If we hear that news this will POP over $10 easy
If we hear that news this will POP over $10 easy
Recent GNPX News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2026 12:05:14 PM
- Genprex Collaborators Present Positive Preclinical Data on Diabetes Gene Therapy for Type 2 Diabetes at the 2026 American Society of Gene and Cell Therapy Annual Meeting • PR Newswire (US) • 05/14/2026 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/13/2026 08:35:46 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 05/11/2026 09:52:40 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/30/2026 12:00:55 PM
- Genprex Receives Patent Grant from The Israel Patent Office for the Combination of Reqorsa® Gene Therapy and PD-1 Antibodies to Treat Cancer • PR Newswire (US) • 04/30/2026 12:00:00 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/29/2026 08:47:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/28/2026 11:07:21 AM
- Genprex Collaborators to Present Positive Preclinical Data on Diabetes Gene Therapy for Type 2 Diabetes at the 2026 American Society of Gene and Cell Therapy Annual Meeting • PR Newswire (US) • 04/28/2026 11:00:00 AM
- Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa® Gene Therapy To Be Released at the 2026 ASCO Annual Meeting • PR Newswire (US) • 04/22/2026 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/21/2026 11:02:55 AM
- Genprex Signs Sponsored Research Agreement to Study Biomarkers that May Predict Patient Response to Reqorsa® Gene Therapy • PR Newswire (US) • 04/21/2026 11:00:00 AM
- Genprex Collaborators Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual Meeting • PR Newswire (US) • 04/20/2026 11:00:00 AM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 04/17/2026 08:34:54 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/30/2026 09:34:58 PM
- Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual Meeting • PR Newswire (US) • 03/18/2026 11:00:00 AM
- Genprex to Participate at BIO Europe Spring 2026 • PR Newswire (US) • 03/10/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2026 11:33:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/23/2026 01:08:16 PM
- Genprex Strengthens Intellectual Property Portfolio with Japanese and EU Patents for Reqorsa® Gene Therapy in Combination with Immunotherapies to Treat Cancer • PR Newswire (US) • 02/23/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/10/2026 01:04:05 PM
- Genprex Announces IP Australia's Intent to Grant Patent for Reqorsa® Gene Therapy in Combination with PD-L1 Antibodies to Treat Cancers • PR Newswire (US) • 02/10/2026 01:00:00 PM
